Liaoning Chengda Biotechnology Co., Ltd. (688739)

Overview

Liaoning Chengda Biotechnology Co.,Ltd. is a prominent player in the biotechnology sector, primarily focusing on the research, development, production, and sales of vaccines for human use. Situated in Shenyang, China, the company was established in 2002. It has carved a niche for itself in the Chinese vaccine market and has expanded its reach to 32 countries worldwide, including India, Pakistan, Thailand, the Philippines, Kenya, Ghana, Malawi, Georgia, among others. The company's commitment to addressing critical health concerns through innovative vaccine solutions has positioned it as a key contributor to global health safety measures.

Products and Services

• Chengda Suda Human Rabies Vaccine

  This vaccine is an essential product in Chengda Biotechnology's portfolio, designed to prevent rabies in humans. The rabies virus is fatal if untreated, and the Chengda Suda Human Rabies Vaccine provides a critical line of defense against this disease. It is a result of the company's extensive research and development efforts, ensuring high efficacy and safety standards.

• Chengda Libao Human Type B Inactivated Encephalitis Vaccine

  Another crucial product offered by Liaoning Chengda Biotechnology is the Chengda Libao Human Type B Inactivated Encephalitis Vaccine. This vaccine targets Japanese encephalitis (JE), a mosquito-borne viral brain infection. JE is prevalent in rural areas in Asia, making this vaccine particularly significant for regions prone to the diseases it helps prevent. The inactivated vaccine is designed to stimulate the body's immune response against the virus without the risk of causing the disease itself.